Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMS NASDAQ:ANIX NASDAQ:APVO NASDAQ:CBIO NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AANIXAnixa Biosciences$3.52+20.1%$3.10$2.07▼$4.20$96.61M0.5861,894 shs579,631 shsAPVOAptevo Therapeutics$1.44-2.0%$2.30$1.40▼$381.10$4.83M5.77168,926 shs210,432 shsCBIOCrescent Biopharma$12.22-2.2%$13.23$10.83▼$63.00$244.18M1.59106,706 shs68,798 shsNERVMinerva Neurosciences$2.25+3.2%$2.07$1.15▼$3.00N/A-0.2619,401 shs38,453 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ANIXAnixa Biosciences+20.14%+18.12%+18.52%-4.35%+5.07%APVOAptevo Therapeutics-2.04%-2.70%-28.00%-48.94%-99.99%CBIOCrescent Biopharma-2.16%-5.64%-11.39%-22.63%-98.41%NERVMinerva Neurosciences+4.90%+3.69%0.00%+22.28%-23.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AANIXAnixa Biosciences$3.52+20.1%$3.10$2.07▼$4.20$96.61M0.5861,894 shs579,631 shsAPVOAptevo Therapeutics$1.44-2.0%$2.30$1.40▼$381.10$4.83M5.77168,926 shs210,432 shsCBIOCrescent Biopharma$12.22-2.2%$13.23$10.83▼$63.00$244.18M1.59106,706 shs68,798 shsNERVMinerva Neurosciences$2.25+3.2%$2.07$1.15▼$3.00N/A-0.2619,401 shs38,453 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ANIXAnixa Biosciences+20.14%+18.12%+18.52%-4.35%+5.07%APVOAptevo Therapeutics-2.04%-2.70%-28.00%-48.94%-99.99%CBIOCrescent Biopharma-2.16%-5.64%-11.39%-22.63%-98.41%NERVMinerva Neurosciences+4.90%+3.69%0.00%+22.28%-23.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/AANIXAnixa Biosciences 3.00Buy$9.00155.68% UpsideAPVOAptevo Therapeutics 3.00Buy$219,040.0015,211,011.11% UpsideCBIOCrescent Biopharma 3.33Buy$25.60109.49% UpsideNERVMinerva Neurosciences 2.00Hold$5.00122.22% UpsideCurrent Analyst Ratings BreakdownLatest NERV, APVO, ADMS, CBIO, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/9/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/27/2025CBIOCrescent BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/25/2025CBIOCrescent BiopharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/19/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/11/2025CBIOCrescent BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.008/5/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/14/2025CBIOCrescent BiopharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$27.006/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$22.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49ANIXAnixa BiosciencesN/AN/AN/AN/A$0.59 per shareN/AAPVOAptevo TherapeuticsN/AN/AN/AN/A$65.21 per shareN/ACBIOCrescent BiopharmaN/AN/AN/AN/A$8.24 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.22 per share10.43($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AANIXAnixa Biosciences-$12.55M-$0.35N/A∞N/AN/A-67.45%-59.18%N/AAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)CBIOCrescent Biopharma-$37.88M-$34.93N/AN/AN/AN/A-106.06%-86.60%N/ANERVMinerva Neurosciences$1.44M$1.481.52N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)Latest NERV, APVO, ADMS, CBIO, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ANIXAnixa Biosciences-$0.10-$0.07+$0.03-$0.07N/AN/A8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/A8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACBIOCrescent BiopharmaN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17ANIXAnixa BiosciencesN/A8.458.45APVOAptevo TherapeuticsN/A2.272.27CBIOCrescent BiopharmaN/A9.219.21NERVMinerva NeurosciencesN/A6.156.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%ANIXAnixa Biosciences29.13%APVOAptevo Therapeutics8.06%CBIOCrescent Biopharma75.19%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%ANIXAnixa Biosciences25.30%APVOAptevo Therapeutics0.01%CBIOCrescent Biopharma4.00%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableANIXAnixa Biosciences532.92 million24.59 millionOptionableAPVOAptevo Therapeutics503.29 million3.28 millionNot OptionableCBIOCrescent Biopharma5019.55 million17.85 millionNo DataNERVMinerva Neurosciences9N/AN/ANot OptionableNERV, APVO, ADMS, CBIO, and ANIX HeadlinesRecent News About These CompaniesMinerva Neurosciences Stock Rises on Strategic Alternatives ReviewAugust 14, 2025 | marketwatch.comStocks to Watch: Gambling.com, GrabAGun, Minerva NeurosciencesAugust 14, 2025 | marketwatch.comMinerva Neurosciences Provides Business Updates and Second Quarter Financial ResultsAugust 14, 2025 | globenewswire.comChandigarh: Minerva enter knockout stage of Gothia Cup 2025July 17, 2025 | msn.comMinerva CEO navigates 'nightmare' lab market to secure new HQ in WoburnJuly 16, 2025 | bizjournals.comMinerva University Named World's Most Innovative University for Fourth Consecutive YearJuly 15, 2025 | uk.finance.yahoo.comFree concert on Minerva’s Municipal Park StageJuly 14, 2025 | morningjournalnews.comMHelsinki Cup: Minerva Academy in Round-16 with thumping 7-0 winJuly 14, 2025 | msn.comMinerva narrowly fell short in final, but won hearts with historic Helsinki Cup campaignJuly 13, 2025 | english.newsnationtv.comEMinerva Academy FC: Defying Odds and Dazzling Europe in Helsinki Cup-2025July 13, 2025 | devdiscourse.comDHelsinki Cup: Minerva Academy in semi-finals, two Finland clubs eliminatedJuly 12, 2025 | english.newsnationtv.comEMinerva Neurosciences Inc. (NERV) Stock Price Today - WSJJuly 11, 2025 | wsj.comMinerva registers fourth win in Helsinki CupJuly 10, 2025 | msn.comHelsinki Cup: Minerva Academy logs twin victoriesJuly 10, 2025 | msn.comMinerva Academy FC's Triumph: An Unstoppable Force in Helsinki Cup 2025July 10, 2025 | devdiscourse.comDHelsinki Cup: Minerva registered its fourth win, creating history by winning the match 9-0July 10, 2025 | news.webindia123.comNMinerva High School Athletic Hall of Fame announces Class of 2025 membersJuly 10, 2025 | msn.comValCUN installs Minerva metal Additive Manufacturing machine at Johns Hopkins UniversityJuly 8, 2025 | metal-am.comMMinerva Avenue Charting Next Steps Following Sudden FireJuly 8, 2025 | msn.comFire destroys popular North Nashville nightclub Minerva AvenueJuly 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025NERV, APVO, ADMS, CBIO, and ANIX Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Anixa Biosciences NASDAQ:ANIX$3.52 +0.59 (+20.14%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.40 -0.12 (-3.52%) As of 08:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Aptevo Therapeutics NASDAQ:APVO$1.44 -0.03 (-2.04%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.14 +1.70 (+118.13%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Crescent Biopharma NASDAQ:CBIO$12.22 -0.27 (-2.16%) As of 09/15/2025 04:00 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Minerva Neurosciences NASDAQ:NERV$2.25 +0.07 (+3.21%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$2.24 -0.02 (-0.67%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
